83 results about "Amylin" patented technology

The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.

A combined insulin and amylin and / or GLP-1 mimetic formulation has been developed wherein the pH of the insulin is decreased so that the amylin and / or GLP-1 remains soluble when mixed together with the insulin. In the preferred embodiment, a bolus insulin is administered by injection before breakfast, providing adequate bolus insulin levels to cover the meal, without producing hypoglycemia after the meal. This can be combined with an adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of the insulin and amylin and / or GLP-1 mimetic combination. A GLP-1 mimetic may be combined with either rapid acting or basal insulin formulations. As a result, a patient using the combination formulation therapy may only need to inject half as many times per day.

The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example amylin, a monoclonal antibody, insulin, Peptide T or analog thereof.

The present invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide, and a meal-related insulin peptide, and to the use of such compositions for treatment of e.g. hyperglycemia.

A combined insulin and amylin and / or GLP-1 mimetic formulation has been developed wherein the pH of the insulin is decreased so that the amylin and / or GLP-1 remains soluble when mixed together with the insulin. In the preferred embodiment, a bolus insulin is administered by injection before breakfast, providing adequate bolus insulin levels to cover the meal, without producing hypoglycemia after the meal. This can be combined with an adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of the insulin and amylin and / or GLP-1 mimetic combination. A GLP-1 mimetic may be combined with either rapid acting or basal insulin formulations. As a result, a patient using the combination formulation therapy may only need to inject half as many times per day.

The present invention relates to immunogenic but non-depositing-forming polypeptides or peptides homologous to amyloid β, prion, amylin or α-synuclein which can be used alone or conjugated to an immunostimulatory molecule in an immunizing composition for inducing an immune response to amyloid β peptides and amyloid deposits, to prion protein and prion deposits, to amylin and amylin deposits, to α-synuclein and deposits containing α-synuclein, or to polyglutamine repeats and deposits of proteins containing polyglutamine repeats. Described are also antibodies directed against such peptides, their generation, and their use in methods of passive immunization to such peptides and deposits.

The invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide and an anionic surfactant, and methods for treatment of hyperglycemia.

The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.

The invention discloses a starch derivative copolymer and a preparation method and application thereof. The starch derivative copolymer is prepared by copolymerizing 30 to 95 percent of amylin maleic acid monoester, 5 to 20 percent of unsaturated carboxylic acid monomer and 0 to 65 percent of other copolymerizable monomer C in aqueous solution at the temperature of 50-100DEG C. The starch derivative copolymer can be used as a cement dispersing agent, a cement mortar additive and a water reducer for concrete, and has the advantages of low cost, good water solubility, good compatibility when compounded with a polycarboxylic acid water reducer, and the like.

The invention uses liquefying enzyme ejecting method to produce low DE value malt dextrin, the invention refers to a kind of enzyme project manufacturing method of low DE value malt dextrin and the application. The invention uses core starch or indica rice powder as materials, uses the special device steam ejecting liquefying device and laminar current device, the product whose DE value is 2-6 is obtained through ejecting, thermal retardation and liquefying, enzyme eliminating process. The product with 5-6 DE value can be used in solid chrysanthemum flower essence beverage to replace 66% sugar powder and decrease 60% chrysanthemum extracting solution; the product with 2-3 DE value can be used in the production of gammon and icecream, the 50% aft in gammon and icecream can be replaced by malt dextrin, 30 g fat in gammon can be replaced with 6-7.5 g malt dextrin, 4 g fat in icecream can be replaced with 1 g malt dextrin. The invention fills the blank of low DE value malt dextrin in our country.

The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.

Provided herein are methods of modulating hormone concentrations in a subject comprising the administration of a composition comprising a chemosensory receptor ligand, wherein the composition is adapted to deliver the ligand to one or more regions of the intestine of said subject. Also provided are methods directed to the modulation of circulating concentrations of one or more of GLP-1 (total), GLP-1 (active), GLP-2, oxyntomodulin, PYY (total), PYY 3-36, CCK, GIP, insulin, C-peptide, glycentin, uroguanylin amylin, and ghrelin (total), ghrelin (active) and glucagon.

The invention relates to a method for preparing anti-aging, antifatigue and essential qi-supplementing granules and capsules. The method comprises: mixing codonopsis pilosula, raidx astragali, mulberry, gordon euryale seed, scorch-fried white atractylodes, Indian buead, manyflower solomonseal rhizom, tuber of multiflower knotweed, wild soybean, Chinese magnoliavine fruit, fragrant solomonseal rhizome, raisin, human placenta, rehmannia glutinosa, south dodder seed, dwarf lilyturf tuber, root of rehmannia, lotus seed, dogwood, cervus elaphus linnaeus, radix glycyrrhizae preparata, Huai yam, stir-fried spiny jujube, dried longan pulp, salvia miltiorrhiza bunge and dark pum fruit; performing two times of extraction by decocting with 8 times of water and decocting with 6 times of water for 2 hours respectively; combining extracts for concentration; drying the extracts to make dry paste; grinding the dry paste obtained at two times into fine powder; adding milk powder, sucrose, amylin, edible essence and vegetable fat powder into the fine powder and mixing the mixture; adding starch serving as an auxiliary material; and making the resulting product into granules or filling the resulting product into hollow capsules to make capsules and bagging the capsules. The granules and capsules of the invention have the advantages of remarkable effect, simple administration, nice taste and toxic or side effect prevention.

The invention provides a frozen beverage with the rice dumpling taste of sticky rice. The frozen beverage includes the ingredients in the following weight percentage: 100-150 parts of sugary, 10-60 parts of milk powder, 5-10 parts of goat milk powder, 20-70 parts of amylin, 50-100 parts of coconut oil, 40-90 parts of cream, 180-220 parts of cooked sticky rice and a stabilizing agent. The frozen beverage has the health-care function and has certain food therapy effect when the user eats the frozen beverage.

Methods and compositions for identifying mutations and polymorphisms in mutant genes encoding gene product involved in insulin secretion, for example, hepatocyte nuclear factor-1∝, glucokinase, amylin and mitochondrial DNA are disclosed. Specifically, a microchip comprising a combination of at least two different mutant genes wherein each gene comprises at least one mutation indicative of a predisposition for type-2 diabetes in a member of a Chinese population is disclosed. A kit comprising the microchip, an isolated nucleic acid, primers and probes which are specifically used to screen or identify the mutations in genes of hepatocyte nuclear factor-1∝, glucokinase, amylin and mitochondrial DNA are also disclosed.

The invention relates to sugarless south isatis root granules and a preparation method thereof. The sugarless south isatis root granules are prepared from south isatis root, dyer woad leaf, amylin and steviosin and are prepared by decoction, concentration, standing, recovery, and drying in proportion. The method changes the original sugar granules into sugarless granules, uses the amylin to replace cane sugar, and adds a small amount of the steviosin to adjust the mouthfeel, reduces the saccharinity of the original sugar granules, and reduces the dosage of auxiliary materials and the cane sugar in the preparation. The applied dosage of the sugarless granules is not changed compared with that of the original sugar granules, so that the sugarless south isatis root granules can adapt to more patients.

Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-γ, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.

The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or analog thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.

Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-γ, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.

The invention discloses a medicament for treating rice blast. The medicament is prepared from 10 to 20 percent of albendazole, 70 to 75 percent of Chinese herbal medicament extracting solution and 5 to 30 percent of auxiliary agent, wherein the Chinese herbal medicament extracting solution is prepared by mixing Chinese herbal medicinal materials such as indigowoad root, baical skullcap root and weeping forsythia according to a mass ratio of 1:1:1 and then extracting the mixture by using 65 percent alcohol; the auxiliary agent is an emulsifying agent and a thickening agent; the emulsifying agent is 4 to 25 percent based on the total mass of all the materials; the thickening agent is 1 to 5 percent based on the total mass of all the materials; the model number of the emulsifying agent is 2201 or 4203; and the thickening agent is amylin or xanthan gum. The medicament for treating rice blast has the characteristics that: the medicinal effect is good and is better than the indoor biological test effect of the conventional medicament for treating rice blast; the bacteriostatic rate reaches 100 percent; field tests prove that the preventing effect reaches to over 90 percent; medicament resistance is difficult to generate; and the medicament cost is low. The medicament for treating the rice blast is suitable for preventing and treating rice blast.

Novel methods for use in identifying or assaying compounds which can simulate the ability of amylin to cause hyperlactemia and hyperglycemia in in vivo biological models, or for use in evaluating the potency of compounds known or suspected to simulate these actions of amylin, which involve introducing test samples into in vivo test systems and determining the presence or amount of a rise in lactate, or determining the presence or amount of a rise in lactate and a rise in glucose, following test sample administration.

The invention relates to a marine oligosaccharide compound with type II diabetes resisting activity, which is a compound which is formed by following steps: taking D-polymannose aldehydic oligosaccharide which comes from sea and contains carboxyl in each oligosaccharide ring, reacting with dilute alkali and chromium salt solution and introducing trivalent chromium ions which is closely relative tothe generation and the development of diabetes into oligosaccharide molecules. A pharmacological experiment proves that the product has remarkable effect on accelerating insulin secretion, is not influenced by amylin and has effects on lightening glucose load, improving blood-lipoid metabolism, insulin sensitivity and certain kidney protection and lightening pancreatic injury for type II diabetesrats and mouse. The product of the invention comes from marine natural species, has the advantages of good security, unique structure, low molecular weight, high chromium binding ratio, good oral absorption effect, and the like, can play a hypoglycemic role in a plurality of links and has favorable market application prospect on the aspect of preventing and treating type II diabetes.

The invention discloses a refining process method for the productionof maltodextrin. The technical proposal of the method is as follows: the prior ion exchange refining system is adjusted, and a macroporous nonpolar adsorption resin column is added behind an adjustment column to form an ion exchange and adsorption resin refining system; a decolorized sugar solution directly enters the adsorption resin column through an ion exchange column for further removal of impurities and peculiar smell, and then is sent to a concentration and drying system to be processed into a dextrine product. The light transmittance of the sugar solution treated by adopting the technical proposal is improved to 96.2 percent from the prior 92.2 percent, and is improved by 3. 28 percent; the chroma is improved to a value less than 15Hz from a value which is averagely less than 40Hz; the white content is improved to 92.5 percent from average 89 percent; and particularly the odor of the product is apparently improved, is reduced to a light odor or no odor from the prior strong acid and base odor and burned odor, and achieves the requirement of customers.

The invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide and a protracted insulin peptide.

Amylin derivatives, pharmaceutical compositions containing such derivatives, as well as methods of treating diabetes and hyperglycaemia are disclosed.

The present invention relates to novel amylin derivatives, pharmaceutical compositions containing such derivatives and to methods of treating diabetes and hyperglycaemia using the amylin derivatives of the invention.

The invention relates to compound jellyfish soluble granules for reducing blood pressure and a preparation method thereof. The compound jellyfish soluble granules are prepared by using jellyfish skin as a raw material through the following steps: desalting, washing and grinding the jellyfish skin, adding water into the obtained product to dilute, adopting alkali protease to carry out enzymolysis to obtain enzyme solution, carrying out enzyme inactivation, decoloration and sterilization on the enzyme solution, and concentrating and drying the obtained solution to obtain an enzymatically hydrolyzed jellyfish extract; proportioning the following Chinese herbal raw materials in percentage by weight: 20 to 40 percent of baical skullcap root, 20 to 40 percent of cassia seed, 10 to 30 percent of processed tuber of multiflower knotweed and 10 to 30 percent of apocynum venetum, decocting and extracting the raw materials to obtain extracting solution, concentrating and drying the extraction solution to obtain extractum, and grinding the extractum to obtain a Chinese herbal extract; and weighing the following materials in percentage by weight: 5 to 20 percent of the enzymatically hydrolyzed jellyfish extract, 20 to 40 percent of powdered sugar, 40 to 60 percent of amylin and 5 to 20 percent of the Chinese herbal extract, adopting ethanol to wet the materials to prepare soft materials, and carrying out granulation and drying on the soft materials. The soluble granules for reducing the blood pressure has the advantages of scientific prescription, rapid adsorption and obvious effect of reducing the blood pressure. The preparation method of the compound jellyfish soluble granules has reasonable process and strong operability and is suitable for industrial production.

Methods and compositions for identifying mutations and polymorphisms in mutant genes encoding gene product involved in insulin secretion, for example, hepatocyte nuclear factor -1∝ glucokinase, amylin and mitochondrial DNA are disclosed. Specifically, a microchip comprising a combination of at least two different mutant genes wherein each gene comprises at least one mutation indicative of a predisposition for type-2 diabetes in a member of a Chinese population is disclosed. A kit comprising the microchip, an isolated nucleic acid, primers and probes which are specifically used to screen or identify the mutations in genes of hepatocyte nuclear factor-1∝ glucokinase, amylin and mitochondrial DNA are also disclosed.

The invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide and an anionic surfactant, and methods for treatment of hyperglycemia.